Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)

Trial Profile

Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2018

At a glance

  • Drugs Nintedanib (Primary) ; Ketoconazole
  • Indications Colorectal cancer; Fallopian tube cancer; Liver cancer; Mycoses; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2018 Results investigating the effects of ketoconazole, a p-glycoprotein inhibitor, and rifampicin, a p-glycoprotein inducer, on the pharmacokinetics of nintedanib from 2 trials (NCT01679613, NCT01770392) published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top